Hexarad Radiology Platform

Hexarad Group Limited is a radiology company at 163 Tower Bridge Road, London, registered in England and Wales. It addresses radiology reporting backlogs and staffing shortages in hospitals, led by co-founders Dr Farzana Rahman and Dr Jaymin Patel.

Its platform combines ReportRad, a subspecialist teleradiology service, with OptiRad, an operational intelligence platform. AI-led allocation matches each scan to a suitable subspecialist radiologist around the clock, with real-time views of demand, capacity and performance. It reports reporting at 150+ NHS and private sites.

• ReportRad: subspecialist teleradiology reporting across modalities.
• AI allocation: matches scans to subspecialist radiologists around the clock.
• OptiRad: operational intelligence dashboard for demand, capacity and performance.
• Peer review: 2 hours for acute and 48 hours for elective reports.
• Quality assurance: ongoing audit of report quality.
• Accreditations: CQC registered, ISO 27001, ISO 9001, ACR Recognized Center for Healthcare-AI.

Provincial hospitals could outsource subspecialist reading of complex CT and MRI studies. Large hospital radiology departments could use OptiRad to monitor reporting turnaround. Any engagement would need local regulatory and data-transfer review.

AI allocation is reported to cut scan allocation time by 90% and the platform to generate over GBP 500k in annual departmental savings, according to headlines on the company news page. Peer review is offered within 2 hours for acute and 48 hours for elective cases. Accreditations include ISO 27001, ISO 9001 and Cyber Essentials Plus.

Radiology demand is rising faster than the radiologist workforce, pushing hospitals toward teleradiology and AI workload allocation. Vietnamese provincial hospitals with limited specialist radiologists could use remote subspecialist reporting, subject to language, regulatory and data-transfer arrangements.

Hexarad Group Limited, company no. 10249971, England and Wales. Funding includes a GBP 4.5 million Series A and a later EUR 13 million growth round led by MTIP. Recognised by TIME among leading healthtech companies in 2025. CQC registered.